
    
      Patients with grade I-II endometriosis and / or endometrioma <4 cm subjected to time
      intercourses or COS/IUI cycles will be subjected to subcutaneous or vaginal progesterone for
      their luteal phase supplementation in time intercourses or IUI cycles.

      The aim of the study protocol will be to compare the efficacy of subcutaneous progesterone
      (25 mg / day; Pleyris, IBSA Institut Biochimique SA) with vaginal progesterone (90 mg / day;
      Crinone, Merck Serono) administered during the luteal phase in term of pelvic pain reduction
    
  